Agonists Exendin-4 (subsequently renamed exenatide, the first FDA approved incretin mimetic), Liraglutide (a longacting DPP-4-resistant GLP-1 receptor agonist), CJC-1131 (a GLP-1 analog engineered for covalent coupling to albumin), Albiglutide (originally referred to as albugon, a recombinant human albumin-GLP-1 protein), ZP10 (an exendin-4 derivative), BIM51077 (subsequently renamed taspoglutide), LY315902 (a DPP-4-resistant GLP-1 analog), LY2428757 (a pegylated GLP-1), LY2199265 (Dulaglutide, an Fc immunoglobulin fusion protein), Semaglutide (a synthetic peptide similar to GLP-1), Lixisenatide (a synthetic peptide similar to exandin-4), and Tirzepatide (LY3298176, a dual agonist of GIP and GLP-1 receptors)
Materials and methods Ethical committee approval (IAEC/NCP/117/2022) was obtained from the Nargund College of Pharmacy (Bengaluru, India)
"Absorption efficacy of Setria L-Glutathione." Nutrition Research , 2021
(PubMed) Giacosa A, Faliva MA, Perna S, Minoia C, Ronchi A, Rondanelli M
02105-1/asset/8468e457-0c7f-4e4c-9b6d-2202dbefa9cb/main.assets/gr1_lrg.jpg)
